Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06138925

Analysis of the Psychometric Properties of Kinematic Parameters of Locomotion Measured by Inertial Measurement Units. Validation in Healthy Children and Children With Cerebral Palsy

Cerebral palsy (CP) is currently one of the major causes of disability in children. The presence of various disorders (muscle stiffness, architectural bone defects, spasticity) leads to a number of functional impacts, including severe impairment of mobility, particularly locomotion. Locomotion can be assessed using a motion capture system that enables 3-dimensional analysis, in order to help make treatment decisions and quantify them. Although these systems are currently considered to be the gold standard, the fact remains that they cause a certain amount of patient fatigue (long set-up times) and that walking is assessed in a laboratory rather than in real life.

Today, technological advances have brought to the fore other gait analysis devices, such as inertial measurement units (IMUs). Various systems incorporating IMUs in the feet, for example, respond to these problems of analysing walking in real-life situations. The IMUs record the movements and orientation of the foot in space; the data is then processed by algorithms to recognise walking steps and calculate the spatio-temporal parameters of locomotion. Additional IMUs positioned on the body can be grafted onto this system to provide a more precise analysis of locomotion, in particular by calculating the movements of the various joints of the lower limb. However, before such devices can be used in a pathological paediatric population, they must be validated in a healthy population. This validation must be conducted using a precise method that has been widely documented in the COSMIN recommendations (Consensus-based Standards for the selection of health Measurement Instruments). The first stage will assess the safety of the IMU devices in a healthy paediatric population, and the validity of the spatio-temporal parameters. If these properties are deemed to be compliant, these same parameters will be assessed in a paediatric population with cerebral palsy in the second stage.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children who have given their consent and whose legal representatives have given their consent
  • Age between 7 and 17 years,
  • Children able to understand simple commands and instructions.
  • Children living within a maximum radius of 50 km of the investigation site.
  • Child covered by national health insurance.

PATIENT GROUP (IN ADDITION TO THOSE ABOVE)

  • Children with proven cerebral palsy resulting in locomotor impairment but able to move around without technical aids (cane, wheelchair).
  • Child covered by national health insurance.

Exclusion criteria

  • Children with a condition other than cerebral palsy that affects their ability to walk.
  • Child subject to a measure of legal protection
  • A child unable to give consent
  • Pregnant, parturient or breast-feeding participant

Treatment and study plan

Analysis of walking

Other

3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)

Analysis of running

Other

analysis of running on flat ground at different speeds (comfortable and fast)

Primary outcomes

  1. Walking speed

    Time frame: During the study visit

    participants' walking speed measured jointly by an IMU system in the shoe and a 3D locomotion analysis system

Study contacts

Contact information is provided by the study sponsor or research team.

Paul ORNETTI

CONTACT

[email protected]

03 80 29 38 72 ext. +33

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Acronym: KAPP-IMU anc

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Nov 18, 2023
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.